Key Statistical Concepts in Clinical Trials for Pharma

This Brief discusses key statistical concepts that facilitate the inferential analysis of data collected from a group of individuals participating in a pharmaceutical clinical trial, the estimation of their clinical significance in the general population of individuals likely to be prescribed the dr...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας: Turner, J. Rick (Συγγραφέας)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: New York, NY : Springer New York, 2012.
Σειρά:SpringerBriefs in Pharmaceutical Science & Drug Development,
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 02287nam a22004335i 4500
001 978-1-4614-1662-3
003 DE-He213
005 20150726161814.0
007 cr nn 008mamaa
008 111012s2012 xxu| s |||| 0|eng d
020 |a 9781461416623  |9 978-1-4614-1662-3 
024 7 |a 10.1007/978-1-4614-1662-3  |2 doi 
040 |d GrThAP 
050 4 |a R-RZ 
072 7 |a MBGR  |2 bicssc 
072 7 |a MED000000  |2 bisacsh 
082 0 4 |a 610  |2 23 
100 1 |a Turner, J. Rick.  |e author. 
245 1 0 |a Key Statistical Concepts in Clinical Trials for Pharma  |h [electronic resource] /  |c by J. Rick Turner. 
264 1 |a New York, NY :  |b Springer New York,  |c 2012. 
300 |a IX, 61 p. 1 illus.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a SpringerBriefs in Pharmaceutical Science & Drug Development,  |x 1864-8118 
520 |a This Brief discusses key statistical concepts that facilitate the inferential analysis of data collected from a group of individuals participating in a pharmaceutical clinical trial, the estimation of their clinical significance in the general population of individuals likely to be prescribed the drug if approved, and the related decision-making that occurs at both the public health level (by regulatory agencies when deciding whether or not to approve a new drug for marketing) and the individual patient level (by physicians and their patients when deciding whether or not the patient should be prescribed a drug that is on the market). These concepts include drug safety and efficacy, statistical significance, clinical significance, and benefit-risk balance. 
650 0 |a Medicine. 
650 0 |a Pharmaceutical technology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Biomedicine general. 
650 2 4 |a Pharmaceutical Sciences/Technology. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9781461416616 
830 0 |a SpringerBriefs in Pharmaceutical Science & Drug Development,  |x 1864-8118 
856 4 0 |u http://dx.doi.org/10.1007/978-1-4614-1662-3  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)